作为癌症治疗目标的AKT
1Institute of Pharmaceutical Science, King's College London, London, UK.
Current topics in microbiology and immunology
|November 18, 2025
概括
在癌症中,PI3K/AKT通路的异常激活是常见的. 虽然像capivasertib这样的AKT抑制剂显示出希望,特别是在特定突变或组合疗法中,但将其转化为广泛的临床益处仍然存在挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 酸-3-酶 (PI3K) 途径的异常激活是人类癌症中经常发生的瘤性事件.
- 作为PI3K致癌功能的关键调解者,AKT一直是重要的治疗点.
- 尽管AKT激活频繁,但AKT抑制剂的临床结果在历史上令人失望.
研究的目的:
- 审查支持人类瘤中AKT依赖性的证据.
- 讨论遗传和细胞环境对AKT依赖的影响.
- 探索将AKT抑制转化为有效的癌症治疗的挑战.
主要方法:
- 对癌症PI3K/AKT通路激活研究的文献综述.
- 对AKT抑制剂的临床试验数据的分析.
- 检查研究AKT依赖性的临床前模型.
主要成果:
- 对于乳腺癌的卡维萨塞蒂布的批准验证了AKT抑制剂的治疗潜力.
- 在罕见的AKT-E17K突变中,AKT抑制剂可能作为单疗法提供益处.
- 组合疗法对更广泛的患者群体具有前景.
结论:
- AKT仍然是一个相关的治疗目标,最近的批准突出了其潜力.
- 了解瘤背景对于有效的AKT向治疗至关重要.
- 克服AKT抑制转化方面的挑战是未来临床成功的关键.
更多相关视频
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
4.3K
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
2.1K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
